Abiopharma

TRAWS PHARMA, INC. (TRAW) Reports the reporting period Financial Results TRAWS PHARMA, INC. (TRAW) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 2790000
• Net Income: 333.77
• EPS: Not disclosed
• Cash and equivalents: 3820000
  • monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis underway Private financing of up to $60M (with $10M of such amount upfront) offering of common stock and milestone
  • year warrants completed on April 15, 2026 supporting operations into Q1 2027 Investor Update call today, April 15, 2026 at 4:30 PM ET NEWTOWN, PA, April 15, 2026 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical
  • stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the year ended December 31, 2025 and provided recent
    • targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease). Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws’ website at https://www.ir.trawspharma.com/partnering. For more information, please visit www.trawspharma.com and follow us on LinkedIn. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933